Wall Street analysts expect that Stemline Therapeutics Inc (NASDAQ:STML) will report $7.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Stemline Therapeutics’ earnings, with estimates ranging from $5.55 million to $11.00 million. Stemline Therapeutics reported sales of $500,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 1,484%. The company is scheduled to report its next earnings results on Thursday, August 8th.

On average, analysts expect that Stemline Therapeutics will report full-year sales of $38.97 million for the current year, with estimates ranging from $23.80 million to $54.38 million. For the next financial year, analysts expect that the business will report sales of $134.20 million, with estimates ranging from $87.36 million to $207.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million for the quarter, compared to the consensus estimate of $2.61 million.

STML has been the subject of several recent analyst reports. ValuEngine upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 4th. BidaskClub downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Zacks Investment Research downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 27th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a research note on Friday, January 25th. Finally, Piper Jaffray Companies reiterated an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Stemline Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.20.

STML traded up $0.03 during trading on Wednesday, hitting $15.13. The stock had a trading volume of 390,160 shares, compared to its average volume of 672,671. The company has a market cap of $659.64 million, a price-to-earnings ratio of -5.06 and a beta of 1.20. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $20.55. The company has a quick ratio of 2.97, a current ratio of 5.07 and a debt-to-equity ratio of 0.01.

In other news, COO Kenneth Hoberman sold 10,557 shares of Stemline Therapeutics stock in a transaction on Monday, February 25th. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ivan Bergstein sold 55,073 shares of Stemline Therapeutics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.11, for a total transaction of $611,861.03. The disclosure for this sale can be found here. Insiders have sold 172,684 shares of company stock valued at $2,042,054 over the last quarter. Insiders own 14.80% of the company’s stock.

Large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stemline Therapeutics during the first quarter worth $36,000. Great West Life Assurance Co. Can acquired a new stake in shares of Stemline Therapeutics during the fourth quarter worth $47,000. Legal & General Group Plc lifted its stake in shares of Stemline Therapeutics by 27.1% during the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,120 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Stemline Therapeutics during the first quarter valued at $102,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in Stemline Therapeutics by 327.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 6,527 shares during the period. Institutional investors and hedge funds own 48.38% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.